会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 7. 发明授权
    • Dipeptidyl peptidase IV inhibitors for the treatment of anxiety
    • 二肽基肽酶IV抑制剂治疗焦虑症
    • US07435420B2
    • 2008-10-14
    • US11397281
    • 2006-04-04
    • Stephan von HoerstenAnts KaskHans-Ulrich DemuthHuu Phuc NguyenSusanne KruberMatthias Hoffmann
    • Stephan von HoerstenAnts KaskHans-Ulrich DemuthHuu Phuc NguyenSusanne KruberMatthias Hoffmann
    • A61K39/00A61K39/38A61K35/00A01N37/18
    • A61K31/426A61K31/40A61K38/2271A61K45/06A61K2300/00
    • The present invention discloses a method for therapeutically treating an animal, including a human, for psychosomatic, depressive and neuropsychiatric diseases, such as anxiety, depression, insomnia, schizophrenia, epilepsy, spasm and chronic pain.Administration of a suitable DP IV inhibitor causes the reduction of activity in the enzyme dipeptidyl peptidase (DP IV or CD 26) or of DP IV—like enzyme activity in the brain of mammals and leads as a causal consequence to a reduced degradation of the neuropeptide Y (NPY) and similar substrates by DP IV and DP IV-like enzymes. Such treatment will result in a reduction or delay in the decrease of the concentration of functionally active neuronal NPY (1-36). As a consequence of the resulting enhanced stability of the endogenous NPY (1-36) caused by the inhibition of DP IV activity, NPY activity is prolonged thereby resulting among other things in functionally active NPY Y1 receptor activity thereby facilitating antidepressive, anxiolytic, analgesic, antihypertension and other neurological effects.
    • 本发明公开了一种治疗性处理动物(包括人)用于心身,抑郁和神经精神疾病如焦虑,抑郁,失眠,精神分裂症,癫痫,痉挛和慢性疼痛的方法。 施用合适的DP IV抑制剂导致哺乳动物脑中的酶二肽基肽酶(DP IV或CD 26)或DP IV样酶活性的活性降低,并导致神经肽降低的降低的因果结果 Y(NPY)和类似底物的DP IV和DP IV样酶。 这种治疗将导致功能活跃的神经元NPY(1-36)的浓度降低或延迟。 由于由抑制DP IV活性引起的内源性NPY(1-36)的增强的稳定性,NPY活性延长,从而导致功能活性的NPY Y1受体活性,从而促进抗抑郁,抗焦虑,止痛, 抗高血压等神经功能。